首页> 外文OA文献 >P2.01-21 Efficacy and Safety of Combing Anlotinib and Erlotinib as a First-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

【2h】

P2.01-21 Efficacy and Safety of Combing Anlotinib and Erlotinib as a First-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

机译：P2.01-21梳理蒽虫和厄洛替尼作为先进非小细胞肺癌患者的一线治疗（NSCLC）的疗效和安全性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
B. Han; T. Chu; C. Shi; H. Zhong; W. Zhang; B. Zhang; R. Zhong; X. Zhang;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. AvaALL: Open-Label Randomized Phase 1Mb Trial Evaluating the Efficacy and Safety of Standard of Care With or Without Continuous Bevacizumab (BV) Treatment Beyond Disease Progression in Patients (pts) With Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) After First-Line (1L) Treatment With BV Plus Platinum-Doublet Chemotherapy (CT) [J] . Clinical advances in hematology & oncology: H&O . 2012,第Suppla11期

机译：AvaALL：开放标签随机1Mb临床试验，评估在初次手术后晚期非鳞状非小细胞肺癌（NSCLC）患者病情进展之外，是否进行持续贝伐单抗（BV）治疗的标准治疗的有效性和安全性BV加上铂金双线化疗（CT）的线（1L）治疗
2. 9170 Safety and efficacy of first-line bevacizumab (Bv) plus chemotherapy in elderly patients (pts) with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): SAiL (MO19390) [J] . P.Garrido, N.Thatcher, L.Crino, European Journal of Cancer Supplements . 2009,第2期

机译：9170贝伐单抗（Bv）一线联合化疗对晚期或复发性非鳞状非小细胞肺癌（NSCLC）老年患者（pts）的安全性和有效性：SAiL（MO19390）
3. Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC) [J] . Faehling M., Achenbach J., Staib P., Journal of Cancer Research and Clinical Oncology . 2018,第7期

机译：Erlotinib在先进的非小细胞肺癌（NSCLC）患者中的常规临床实践中的常规临床实践
4. The clinical efficacy of transfusion of cytokine-induced killer cells combined with chemotherapy and XiaoJi decoction in patients with stage IIIB/IV non-small cell lung cancer [C] . Liuning Li, Jiaying Liu, Xiaoshu Chai, IEEE International Conference on Bioinformatics and Biomedicine . 2014

机译：细胞因子诱导的杀伤细胞输注结合化学疗法和消积汤治疗IIIB / IV期非小细胞肺癌的临床疗效
5. Predictors of changes in health-related quality of life during chemotherapy in an advanced non-small cell lung cancer patient population [D] . Shallwani, Shirin Mehdi 2010

机译：非小细胞肺癌晚期患者化疗期间健康相关生活质量变化的预测因子
6. Prospective Evaluation of First-Line Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation: A Multicenter Academic Phase II Study in Caucasian Patients (FIELT) [O] . Jacques De Grève, Jan Van Meerbeeck, Johan F. Vansteenkiste, -1

机译：一线厄洛替尼治疗晚期非小细胞肺癌（NSCLC）进行EGFR活化突变的前瞻性评估：白人患者多中心学术II期研究（FIELT）
7. P1.01-95 Efficacy and Safety of Anlotinib in Combination with Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients [O] . B. Han, T. Chu, X. Zhang, 2019

机译：P1.01-95 Anlotinib与化疗结合化疗的疗效和安全性作为先进的非小细胞肺癌（NSCLC）患者的一线治疗

P2.01-21 Efficacy and Safety of Combing Anlotinib and Erlotinib as a First-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

著录项

引文网络

相似文献

相关主题

期刊订阅